Alembic Pharma Q2 net surges 81% to ₹335 crore

HYDERABAD Alembic Pharmaceuticals shares were in the spotlight Wednesday after the generic drugmaker reported more than 81% year-on-year surge in consolidated net profit to ₹335 crore during September quarter. The profit came on a 36% increase in the revenue from operations to ₹2,603 crore. The company also announced expansion of its collaboration with DifGen Pharmaceuticals that will help it sharpen focus on the key U.S. market.

Alembic shares touched 20% intra-day before paring gains to close nearly 13% higher at ₹907.20 apiece on the BSE. Alembic Pharma gets U.S. FDA nod for generic chronic constipation drug Alembic Pharma gets U.S. FDA nod for generic chronic constipation drug Alembic Pharma gets U.S.

FDA nod for generic chronic constipation drug storyline 1 On the Q2 FY27 results, Managing Director Pranav Amin said the “U.S business was driven by strong volume growth and new launches. In U.S.